We have located links that may give you full text access.
Comparison of the SenSmart™ and the INVOS™ neonatal cerebral near-infrared spectrometry devices.
OBJECTIVES: To determine the correlation and agreement between the SenSmart™ and the INVOS™ devices of neonatal cerebral regional oxygen saturation (CrSO2 ) measurements using neonatal sensors. The secondary objective was to develop a regression model that predicts CrSO2 -INVOS values using CrSO2 -SenSmart indices and determine whether the values between the devices are interchangeable.
METHODS: A prospective, cross-sectional study was conducted in infants during the first 4 weeks of life. Simultaneous, bilateral CrSO2 was measured using the SenSmart™X100 (CrSO2 -SenSmart) or INVOS™ 5100C (CrSO2 -INVOS) device in each frontoparietal area for 2 h. Five-minute CrSO2 values were extracted for analysis.
RESULTS: Thirty infants were recruited with 720 pairwise measurements and 26 (84%) were evaluated in the first week of life. Mean gestational age of the preterm and term infants was [30.9 ± 2.8 ( n = 14) and 38.8 ± 1.1 ( n = 16)] weeks, respectively. Overall CrSO2 - was 77.08 ± 9.70% and 71.45 ± 12.74% for the SenSmart and INVOS, respectively ( p < 0.001). The correlation coefficient ( r ) between the CrSO2 -SenSmart and INVOS was 0.20 ( p < 0.001). The mean difference between the CrSO2 -SenSmart and INVOS was 5.63 ± 13.87% with -21.6% to 32.8% limits of agreement. The r and mean difference was 0.39 ( p < 0.001) and 8.87 ± 12.58% in preterm infants, and 0.06 ( p = 0.27) and 2.79 ± 14.34 in term infants.
CONCLUSION: The CrSO2 -SenSmart tended to read higher than the CrSO2 -INVOS device. There was no correlation between the CrSO2 -SenSmart and the CrSO2 -INVOS in term infants and it was weak in preterms. Due to imprecise agreement, the CrSO2 -SenSmart values are not interchangeable with those of the CrSO2 -INVOS.
METHODS: A prospective, cross-sectional study was conducted in infants during the first 4 weeks of life. Simultaneous, bilateral CrSO2 was measured using the SenSmart™X100 (CrSO2 -SenSmart) or INVOS™ 5100C (CrSO2 -INVOS) device in each frontoparietal area for 2 h. Five-minute CrSO2 values were extracted for analysis.
RESULTS: Thirty infants were recruited with 720 pairwise measurements and 26 (84%) were evaluated in the first week of life. Mean gestational age of the preterm and term infants was [30.9 ± 2.8 ( n = 14) and 38.8 ± 1.1 ( n = 16)] weeks, respectively. Overall CrSO2 - was 77.08 ± 9.70% and 71.45 ± 12.74% for the SenSmart and INVOS, respectively ( p < 0.001). The correlation coefficient ( r ) between the CrSO2 -SenSmart and INVOS was 0.20 ( p < 0.001). The mean difference between the CrSO2 -SenSmart and INVOS was 5.63 ± 13.87% with -21.6% to 32.8% limits of agreement. The r and mean difference was 0.39 ( p < 0.001) and 8.87 ± 12.58% in preterm infants, and 0.06 ( p = 0.27) and 2.79 ± 14.34 in term infants.
CONCLUSION: The CrSO2 -SenSmart tended to read higher than the CrSO2 -INVOS device. There was no correlation between the CrSO2 -SenSmart and the CrSO2 -INVOS in term infants and it was weak in preterms. Due to imprecise agreement, the CrSO2 -SenSmart values are not interchangeable with those of the CrSO2 -INVOS.
Full text links
Trending Papers
Monitoring Macro- and Microcirculation in the Critically Ill: A Narrative Review.Avicenna Journal of Medicine 2023 July
Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium-Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction.Diabetes Care 2023 November 22
ASA Consensus-based Guidance on Preoperative Management of Patients on Glucagon-like Peptide-1 Receptor Agonists.Anesthesiology 2023 November 21
Tranexamic Acid for Traumatic Injury in the Emergency Setting: A Systematic Review and Bias-Adjusted Meta-Analysis of Randomized Controlled Trials.Annals of Emergency Medicine 2023 November 22
Association between postinduction hypotension and postoperative mortality: a single-centre retrospective cohort study.Canadian Journal of Anaesthesia 2023 November 22
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app